Latanoprost-related transient incontinence.
Latanoprost has increasingly become the first choice in topical anti-glaucoma therapy. Local adverse events like hypertrichosis and increased iris pigmentation are common whereas systemic adverse events have been rare and mild in intensity. The authors would like to report a case of transient urge incontinence after initiation of latanoprost therapy confirmed by challenge-rechallenge tests and speculate on the causal relationship.
Raja
Vignesh
V
Sandanshiv
Pravin
P
Asghar
Muhammad
M
Moriarty
Brendan
B
D000959:Antihypertensive Agents / Q000009:adverse effects*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006068:Gonioscopy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects*; D053202:Urinary Incontinence, Urge / Q000139:chemically induced*; D014563:Urodynamics
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost